Switch theme
Sign up to access all valuation multiples
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
2014
78
LTM Revenue $11.7M
LTM EBITDA n/a
-$0.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Affimed has a last 12-month revenue of $11.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Affimed achieved revenue of $8.3M and an EBITDA of -$102M.
Affimed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Affimed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $41.4M | $8.3M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$81.5M | -$102M | XXX | XXX | XXX |
| EBITDA Margin | -197% | -1237% | XXX | XXX | XXX |
| Net Profit | -$57.5M | -$86.0M | XXX | XXX | XXX |
| Net Margin | -139% | -1039% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Affimed's stock price is $1.
Affimed has current market cap of $13.0M, and EV of -$0.7M.
See Affimed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$0.7M | $13.0M | XXX | XXX | XXX | XXX | $-3.81 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Affimed has market cap of $13.0M and EV of -$0.7M.
Affimed's trades at -0.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Affimed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Affimed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$0.7M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.0x | XXX | XXX | XXX |
| P/E | -0.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAffimed's NTM/LTM revenue growth is 109%
Affimed's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.5M for the same period.
Over next 12 months, Affimed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Affimed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Affimed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -80% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1237% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1128% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 298% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1148% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1443% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Affimed acquired XXX companies to date.
Last acquisition by Affimed was XXXXXXXX, XXXXX XXXXX XXXXXX . Affimed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Affimed founded? | Affimed was founded in 2014. |
| Where is Affimed headquartered? | Affimed is headquartered in United States of America. |
| How many employees does Affimed have? | As of today, Affimed has 78 employees. |
| Who is the CEO of Affimed? | Affimed's CEO is Dr. Andreas Harstrick, M.D.. |
| Is Affimed publicy listed? | Yes, Affimed is a public company listed on NAS. |
| What is the stock symbol of Affimed? | Affimed trades under AFMD ticker. |
| When did Affimed go public? | Affimed went public in 2014. |
| Who are competitors of Affimed? | Similar companies to Affimed include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Affimed? | Affimed's current market cap is $13.0M |
| What is the current revenue of Affimed? | Affimed's last 12-month revenue is $11.7M. |
| What is the current EV/Revenue multiple of Affimed? | Current revenue multiple of Affimed is -0.1x. |
| What is the current revenue growth of Affimed? | Affimed revenue growth between 2023 and 2024 was -80%. |
| Is Affimed profitable? | Yes, Affimed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
